Table 2 Doses of each DOAC for approved indications in Europe, the USA, and Japan
From: Profiles of direct oral anticoagulants and clinical usage—dosage and dose regimen differences
VTE prevention (V) | SPAF (S) | (S)/(V) daily dose ratio | |||
|---|---|---|---|---|---|
Dose | Area | Dose | Area | ||
Dabigatran | 220 mg OD | EU | 150 mg BID 110 mg BID | EU, JP | 1–1.4 |
150 mg BID | US | – | |||
Rivaroxaban | 10 mg OD | EU, US | 20 mg OD | EU, US | 2 |
15 mg OD | JP | – | |||
Apixaban | 2.5 mg BID | EU | 5 mg BID | EU, US, JP | 2 |
Edoxaban | 30 mg OD | JP | 60 mg OD 30 mg OD | EU, US, JP | 2 |